Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 8, 2026

Boston Scientific Corp (BSX)

A forensic read on Boston Scientific Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

A · High-quality compounder

Forensic grade

Safe

Financial health

5.3

Distress distance

Clean

Earnings quality

Forensic signals

19.5

P / E (ttm)

12.0%

ROE

$71.4B

Market cap

0.00%

Dividend yield

19.9%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Boston Scientific Corp earns an A (High-quality compounder) forensic quality grade, and its balance-sheet distress test reads 5.3, placing it in the Safe zone. 5 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+1.3%/yr

FY2022–FY2025

Share-count dilution. Diluted share count changed +4% over the last 3 years to FY2025 (+1.3%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~4%.

stopped

FY2023→FY2024

Shareholder returns — halted. Capital returns have STOPPED — $28M of buybacks + dividends in FY2023, but ~$0 in FY2024. A halt usually means the company is conserving cash.

suspended

FY2023→FY2024

Dividend — suspended. The dividend has been SUSPENDED — $28M paid in FY2023, then $0 in FY2024. A suspension is a major signal the board is conserving cash; the prior payment history doesn't offset it.

8.4%

FY2025

Return on invested capital. Return on invested capital is 8.4% in the latest fiscal year and rising from 4% — around its ~10% cost of capital, so growth is roughly value-neutral.

$73M

FY2020–FY2020

Goodwill impairments. Took $73M of goodwill writedowns across 1 year (FY2020 ($73M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$20.07B

Revenue Growth YoY+19.9%

Revenue CAGR (3yr)+16.5%

Net Margin14.4%

Free Cash Flow$3.66B

Return on Equity12.0%

Debt / Equity0.47x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Boston Scientific Corp's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 8, 2026. Forensic signals flag probability, not certainty.